Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Leflunomide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Wanbang’s Leflunomide Tablets Get FDA Nod, Set to Enter U.S. Market
Details : Leflunomide is an immunomodulatory drug that inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), in patients with rheumatoid arthritis.
Product Name : Leflunomide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2020
Lead Product(s) : Leflunomide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable